Compare Ascendis Pharma A/S (ASND) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.21. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| ASND | QCLN | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $68.47 |
52-Week Low | $189.74 | $36.11 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
QCLN trades at $53.17, up 2.15% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights clean energy ETF growth driven by data center demand and geopolitical shifts, though regulatory hurdles and supply chain costs pose challenges. The stock lacks disclosed financial ratios, requiring deeper fundamental review.
Outlook is cautiously optimistic given sector tailwinds, but investment hinges on policy stability and cost management. Risks include U.S. permit delays and Chinese trade tensions, while institutional sentiment appears mixed amid volatile clean energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
